| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Citric acid-13C6 itself does not have a traditional biological target; it is a stable isotope-labeled tracer. The parent compound citric acid is a key intermediate in the citric acid cycle (Krebs cycle), which is central to cellular respiration in aerobic organisms. Citric acid-13C6 is used to track carbon flux through metabolic pathways, including the TCA cycle, gluconeogenesis, and fatty acid synthesis. It serves as a metabolic tracer for studying energy metabolism and biosynthetic pathways.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Citric acid-13C6 does not exhibit direct in vitro biological activity as it is an isotopically labeled tracer rather than a bioactive compound. However, the parent compound citric acid is a naturally occurring metabolite involved in energy production and biosynthesis. In cell culture studies, citric acid-13C6 is used to trace metabolic pathways by monitoring the incorporation of ¹³C into downstream metabolites using mass spectrometry. |
| ln Vivo |
Citric acid-13C6 is not administered as a therapeutic agent; it is used as a metabolic tracer in in vivo studies. When administered to animal models, it allows researchers to track carbon flow through metabolic pathways, including the TCA cycle, lipogenesis, and gluconeogenesis. The labeled compound is used to study metabolic flux, assess mitochondrial function, and investigate metabolic disorders such as diabetes and obesity.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for citric acid-13C6 are not applicable, as it is a metabolic tracer rather than a bioactive compound. Quality control assays involve HPLC or mass spectrometry to verify isotopic purity (≥98 atom % ¹³C) and chemical purity. The compound is also tested for solubility and stability under recommended storage conditions. It is soluble in water and other polar solvents.
|
| Cell Assay |
In vitro cellular assays for citric acid-13C6 involve metabolic tracing studies rather than traditional bioactivity assays. Cells are cultured in media containing citric acid-13C6, and the incorporation of ¹³C into metabolic intermediates is measured by LC-MS or GC-MS. These studies allow researchers to quantify metabolic flux through the TCA cycle and other pathways. The compound is used to study cellular metabolism in various cell types, including cancer cells and primary cells.
|
| Animal Protocol |
In vivo animal studies for citric acid-13C6 involve metabolic tracing experiments. Animals are administered citric acid-13C6 via oral, intravenous, or intraperitoneal routes. Blood, tissues, and excreta are collected at various time points, and the ¹³C enrichment in metabolites is measured by mass spectrometry. These studies provide insights into whole-body metabolism, including glucose and lipid metabolism, and are used in metabolic disease research.
|
| ADME/Pharmacokinetics |
Citric acid-13C6 has a molecular formula of ¹³C₆H₈O₇ and a molecular weight of 198.08. The compound appears as a white crystalline powder with a purity of ≥98% and an isotopic enrichment of ≥98 atom % ¹³C. It is soluble in water and is stable under recommended storage conditions. The compound is intended for research use only and is not for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of citric acid-13C6 is not extensively characterized, as it is a stable isotope-labeled tracer rather than a therapeutic agent. The parent compound citric acid is generally recognized as safe (GRAS) as a food additive and is naturally present in the body. Standard safety data for handling isotopically labeled compounds in laboratory settings would apply. Citric acid-13C6 is intended for research use only and is not approved for clinical use.
|
| References |
|
| Additional Infomation |
Citric acid-13C6 (CAS 287389-42-8) is a uniformly ¹³C-labeled isotopologue of citric acid, wherein all six carbon atoms are substituted with the stable carbon-13 isotope. It has a molecular formula of ¹³C₆H₈O₇ and a molecular weight of 198.08. Citric acid is a weak organic tricarboxylic acid found in citrus fruits and is a natural preservative. This labeled compound is essential for studies involving metabolic pathways, the Krebs cycle, and cellular respiration. It is intended for research use only and is not approved for clinical use.
|
| Molecular Formula |
13C6H8O7
|
|---|---|
| Molecular Weight |
198.08
|
| Exact Mass |
198.047
|
| CAS # |
287389-42-8
|
| Related CAS # |
Citric acid;77-92-9
|
| PubChem CID |
16217547
|
| Appearance |
White to light yellow solid powder
|
| Melting Point |
153-159 °C(lit.)
|
| LogP |
-1.7
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
13
|
| Complexity |
227
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[13CH2]([13C](=O)O)[13C]([13CH2][13C](=O)O)([13C](=O)O)O
|
| InChi Key |
KRKNYBCHXYNGOX-IDEBNGHGSA-N
|
| InChi Code |
InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/i1+1,2+1,3+1,4+1,5+1,6+1
|
| Chemical Name |
2-hydroxy(1,2,3-13C3)propane-1,2,3-tricarboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ~100 mg/mL (~504.9 mM; with ultrasonication)
DMSO: ~100 mg/mL (~504.9 mM; with ultrasonication) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (12.62 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Suspended solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0485 mL | 25.2423 mL | 50.4847 mL | |
| 5 mM | 1.0097 mL | 5.0485 mL | 10.0969 mL | |
| 10 mM | 0.5048 mL | 2.5242 mL | 5.0485 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
